{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:08:17Z","timestamp":1774289297811,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.thromres.2022.09.021","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:32:06Z","timestamp":1664411526000},"page":"5-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study"],"prefix":"10.1016","volume":"220","author":[{"given":"John","family":"Podstawka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Bolster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery M.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Dawn","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rydz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-9722","authenticated-orcid":false,"given":"Haowei L.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2022.09.021_bb0005","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00277-016-2703-1","article-title":"Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis","volume":"95","author":"Khodadi","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0010","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2022.09.021_bb0015","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2022.09.021_bb0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ajh.25301","article-title":"Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting","volume":"94","author":"Bylsma","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0025","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/rth2.12423","article-title":"Second-line treatments and outcomes for immune thrombocytopenia: a retrospective study with electronic health records","volume":"4","author":"Lal","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.09.021_bb0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/CLEP.S229266","article-title":"Treatment patterns among adults with primary immune thrombocytopenia diagnosed in hematology clinics in the United States","volume":"12","author":"McGrath","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ajh.23580","article-title":"Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity","volume":"89","author":"Moulis","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0040","article-title":"Access to thrombopoietin receptor agonist medications for patients with immune thrombocytopenia across Canada","author":"Britto","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.thromres.2022.09.021_bb0045","series-title":"Statistics Canada Catalogue no. 82-003-XPE. Health Reports","first-page":"3","article-title":"A comparison of individual and area-based socioeconomic data for monitoring social inequalities in health","volume":"20","author":"Pampalon","year":"2009"},{"key":"10.1016\/j.thromres.2022.09.021_bb0050","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.09.021_bb0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjh.16161","article-title":"Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis","volume":"188","author":"Puavilai","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0060","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/09537104.2018.1543864","article-title":"Comparison of treatments for persistent\/chronic immune thromboycytopenia: a systematic review and network meta-analysis","volume":"30","author":"Arai","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2022.09.021_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.22374\/cjgim.v15i4.450","article-title":"Second-line therapy for immune thrombocytopenia: real-world experience in Canada","volume":"15","author":"Nazaryan","year":"2020","journal-title":"Can. J. Gen. Int. Med."},{"key":"10.1016\/j.thromres.2022.09.021_bb0070","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.26404","article-title":"Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: the multicenter, prospective ELEXTRA study","volume":"97","author":"Moulis","year":"2022","journal-title":"Am J Hematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bjh.17804","article-title":"A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK","volume":"196","author":"Rampotas","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0080","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12888","article-title":"The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a french observational study","volume":"165","author":"Mahevas","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0090","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.12139","article-title":"Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists","volume":"53","author":"Ghadaki","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.thromres.2022.09.021_bb0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajh.26045","article-title":"Immune thrombocytopenia (ITP) world impact survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment","volume":"96","author":"Cooper","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.09.021_bb0100","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/jth.15366","article-title":"Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: communication from the ISTH SSC subcommittee on platelet immunology","volume":"19","author":"Al-Samkari","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.09.021_bb0105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jth.13267","article-title":"Increased susceptibility to infections before the diagnosis of immune thrombocytopenia","volume":"14","author":"Ekstrand","year":"2016","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822004030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822004030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:48Z","timestamp":1758736128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822004030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":21,"alternative-id":["S0049384822004030"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.09.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}